Purpose. Acinetobacter baumannii is a major cause of multidrug-resistant nosocomial infections. The characteristics of A. baumannii at two hospitals in a city in Central Brazil are described by analysing the phenotypes and molecular profiles of isolates recovered from 87 patients.
INTRODUCTION
Healthcare-associated infections (HAIs) caused by multidrug-resistant (MDR) Acinetobacter baumannii are associated with a longer hospital stay and higher hospital costs and mortality [1, 2] . Pneumonia associated with mechanical ventilation (VAP) is the nosocomial infection most frequently caused by A. baumannii, especially in intensive care units (ICUs) [1] [2] [3] . A. baumannii intrinsically produces blactamase, which confers resistance to some cephalosporins [4] and can acquire new genes that confer resistance to carbapenems through the production of Ambler class D b-lactamases [5] . A recent study showed that 47 % of A. baumannii isolates in North America are MDR [6] . A 2016 European Centre for Disease Prevention and Control surveillance report showed that 43.3 % of European A. baumannii isolates presented combined resistance to fluoronoquinolones, amynoglicosides and carbapenems, while 49 % were resistant to carbapenems [7] . In Brazil, resistance to carbapenems has increased over the years from 12.6 % (1997-1999) to 71 % (2008-2010) , and this rate is comparable to those observed in other South American countries [8] .
Several Ambler class D b-lactamase genes have been linked to carbapenem resistance in A. baumannii, including blaOXA-23, blaOXA-24 (and its variants blaOXA-40 and blaOXA-72), blaOXA-58, blaOXA-143 and blaOXA-235 [5, 9, 10] . Additionally, genomic insertions such as ISAba1 upstream of the blaOXA-23 and blaOXA-51 genes may increase antimicrobial resistance [5, [11] [12] [13] .
A. baumannii isolates can be classified according to their genetic diversity, which assists in investigations of outbreaks and provides insights into the geographical spread of this micro-organism. Multilocus sequence typing (MLST) is widely used to identify the sequence type (ST) of isolates. In South America, the most frequently observed clonal variants are ST15, ST25, ST79 and ST1 [14] . In Brazil, ST15, ST79 and ST1 are frequently reported in different regions [15, 16] . These STs can be classified as international clones [17] . Three of them (I, II and III) have been linked to several outbreaks in Europe [18] . These three clones correspond to MLST clonal complexes (CCs) CC1, CC2 and CC3, respectively. CC25, CC79, CC15 and CC1 have been reported frequently in South America, including Brazil [14, 16, 19, 20] .
The objective of this work was to evaluate the genetic diversity, resistance profiles and prevalence of genes conferring antimicrobial resistance to A. baumannii isolates at two hospitals in Cuiab a, Mato Grosso, Central Brazil. The analyses were conducted with reference to patients' clinical characteristics and outcomes.
METHODS
Obtaining isolates of Acinetobacter spp. Acinetobacter spp. isolates were derived from patients admitted to two hospitals in Cuiab a, Mato Grosso, Central Brazil: Júlio Muller University Hospital (public, 118 beds) and Jardim Cuiab a Hospital (private, 139 beds). Both are general hospitals and comprise a maternity ward and surgical centre with several specializations. Both have adult ICUs (8 and 20 beds in the public and private hospitals, respectively) as well as neonate ICUs (10 and 7 beds in the public and private hospitals, respectively). The private hospital also has a paediatric ICU (five beds). Blood, urine, or exudate samples were collected from patients between January 2011 and July 2015 to investigate infection or for routine surveillance by hospital infection control committees. Microorganism identification and drug resistance profiles based on minimum inhibitory concentration (MIC) were performed using the Bact/Alert 3D and Vitek2 systems (Bio-M erieux, Marcy l'Etoile, France) in the Microbiology Laboratory of Júlio Muller University Hospital. Samples from the private hospital were transported in brain heart infusion (BHI) medium to the same laboratory in the public hospital. Isolates identified as Acinetobacter spp. were characterized as being sensitive or resistant, or as showing intermediate resistance to antimicrobials according to 2017 Clinical and Laboratory Standards Institute guidelines [21] .
Patient data
Patients' data were obtained from medical records. Sex, age, duration of hospitalization, hospital and hospitalization sector, type of infection, diagnosis of sepsis, antibiotic therapy and outcome were recorded. Risk factors for nosocomial infection, such as mechanical ventilation, central venous access, or bladder or nasoenteral catheter were also noted. Patients without signs of infection who had samples that were positive for Acinetobacter spp. in surveillance cultures were considered to be colonized. The research protocol (#850.791) was approved by the Ethics Research Committee of Júlio Muller Hospital, and was registered in the National System of the Ethical Evaluation of Human Research Projects (CAAE 28637414.0.0000.5541).
Genomic DNA extraction
Isolates of A. baumannii were inoculated in 3 ml of BHI broth and incubated overnight at 37˚C and 200 r.p.m with OD 600 =2.1. After centrifugation, the pellet was resuspended in lysis buffer (proteinase K) and DNA was extracted via the phenol/chloroform method, isopropanol-precipitated, resuspended in ultrapure water and stored at À20 C [22] . 
Detection of

Application of the MLST technique
Some of the A. baumannii isolates were subjected to amplification and sequencing of the seven standard A. baumannii genes (cpn60, fusA, gltA, pyrG, recA, rplB and rpoB) by MLST according to the protocol developed at the Pasteur Institute (www.pasteur.fr/recherche/genopole/PF8/mlst/ Abaumannii.html). The samples were purified and sequenced on an ABI-3500 automatic sequencer (Thermo Fisher Scientific, Waltham, MA, USA) and the data were analysed with CLC DNA Workbench v.6.0 software (Qiagen, Hilden, Germany). The gene sequences were edited and compared to those in the MLST database (http:// pubmlst.org/abaumannii/). eBURST v3 was used to classify the STs into groups of MLST CCs and analyse genetic diversity.
Data analysis
Data on patient age, sex, institution, type of infection, infection topography, colonization and treatment outcome were stored in the EpiData Entry v.3.1 data bank (http://www. epidata.dk/). Associations between clinical or epidemiological characteristics as well as resistance and genotype profiles were analysed using appropriate tests for categorical variables and continuous normal or parametric distributions using EpiData Analysis v.2.2 software (http://www.epidata. dk/). A 5 % value was used as the maximum alpha error limit allowed to reject the null hypothesis. The odds ratio was calculated along with the 95 % confidence interval (CI).
Stepwise logistic regression models using the backwards technique were constructed using Stata v.11.0 software (StataCorp, College Station, TX, USA) to evaluate outcomes of interest (resistance to imipenem or death). Logistic regression (LR) models were generated by the backwards stepwise technique and included variables with P<0.1. Variables and some remaining categories were automatically removed from the model by collinearity or estimation. When appropriate, more than one LR model was presented for the same analysis, suppressing or adding variables to avoid collinearity. Pearson's goodness-of-fit test was used to evaluate the adequacy of adjustment in multivariate models.
RESULTS
Data from patients with A. baumannii infection or colonization A. baumannii isolates were obtained from 87 patients, including 55 males (63.2 %). The mean age was 52.8 ±22.3 years (range, 1 to 91 years). Patients were admitted between 2011 and 2015. Fifty-eight (66.7 %) of the patients were admitted to the public hospital and 29 (33.3 %) were admitted to the private one. The temporal sequence of the hospitalizations did not allow the characterization of A. baumannii outbreaks in both hospitals at any given time. Of the 87 patients, 61 (70.2 %) developed HAIs (48 h after hospitalization), while in the other 26 (29.8 %) patients without clinical findings of infection, A. baumannii was detected in surveillance cultures and they were therefore considered to be colonized. The median number of days between hospitalization and the isolation of A. baumannii was 27.5 days (quartiles=9-46) and the median length of the time between the isolation of A. baumannii and the outcome (hospital discharge or death) was 11.5 days (quartiles=4-35).
The median length of hospital stay was 40 days (quartiles=23-85). Most patients were hospitalized in an adult ICU (n=45, 51.7 %), whereas 21 (24.1 %) were in internal medicine wards and 14 (16.1 %) were in surgical clinical wards. Nineteen patients who were hospitalized in wards required transfer to the ICU.
A. baumannii isolates were obtained from the following biological specimens: sputum, tracheal aspirate, or bronchoalveolar lavage fluid (n=45, 51.7 %); urine (n=12, 13.8 %); rectal swab (n=12, 13.8); blood (n=6, 6.9 %); cutaneous wound exudate (n=6, 6.9 %); and other forms (n=9, 10.3 %). Among the 87 patients, 22 were admitted for communityacquired infections. They were treated empirically, but cultures were only collected from nine patients. Two of them had a community-acquired urinary infection with positive E. coli cultures. There was no culture that was positive for A. baumannii at the time of hospitalization.
Sepsis was diagnosed in 65 (74.7 %) patients; 61 out of 65 had A. baumannii in at least 1 episode of sepsis. Another four patients presented sepsis without isolation of the responsible bacterium, but had A. baumannii-positive surveillance cultures during hospitalization. In 23 out of the 61 patients with sepsis by A. baumannii, other micro-organisms were isolated for 30 septic events (Pseudomonas spp., n=10; Klebsiella spp., n=4; Candida spp., n=4; E. coli, n=3; Serratia spp., n=2; Staphylococcus aureus, n=2; Enterobacter spp., n=1; Stenotrophomonus maltophilia, n=1; Morganella spp., n=1; Enterococcus faecium, n=1; Burkholderia cepacia, n=1), with 18 occurring before and 12 after the isolation of A. baumannii.
The causes of hospitalization among the 61 patients who later developed A. baumannii HAIs were acute surgical pathology or abdominal neoplasia requiring surgery (n=18, 29.5 %); community-acquired infection (n=15, 24.6 %); cardiovascular disease (n=6, 9.8 %); chronic lung disease (n=3, 4.9 %); neurological diseases (n=5, 8.2 %); neoplasm (n=4, 6.6 %); and other diseases (n=10, 16.4 %). The causes of hospitalization among the colonized patients were acute surgical pathology or abdominal neoplasia requiring surgery (n=6, 23.1 %); community-acquired infection (n=7, 26.9 %); cardiovascular disease (n=2, 7.7 %); chronic lung disease (n=3, 11.5 %); neurological disease (n=1, 3.8 %); neoplasm (n=1, 3.8 %); and other diseases (n=6, 23.1 %) (P=0.205).
Among the 61 patients HAI who developed A. baumannii sepsis, the most common type was VAP (n=36, 59.0 %), followed by urinary tract infection (n=9, 14.8 %). Six (9.8 %) patients had bloodstream infections, while six had skin or subcutaneous infections due to cellulitis or pressure ulcers. Four (6.6 %) had infection at the surgical site. Sixty-three patients (72.4 %) required ventilatory support, 64 (73.6 %) received central venous access, 65 (74.7 %) had a bladder catheter and 64 (73.6 %) had a nasoenteral tube.
Prior to the isolation of A. baumannii, 72 patients had used or were using antibiotics to treat infections. The most commonly used antibiotics were piperacillin/tazobactan (n=46, 52.9 %); imipenem (n=34, 39.1 %); cefepime (n=30, 34.5 %); and ceftriaxone (n=11, 12.6 %). After the isolation of The frequency of the blaOXA-23, blaOXA-24, blaOXA-143, blaOXA-58, blaKPC and blaNDM genes and the ISAba1 genomic insertion upstream to blaOXA-23 and blaOXA-51 is shown in Table 1 . The pattern of resistance to imipenem was verified for each gene. The blaOXA-23 gene was frequently detected (68, 78.2 %) and was strongly associated with imipenem resistance (P=0.005). Additionally, 54 (79.4 %) out of 68 bla-OXA23-positive isolates also had the ISAba1 genomic insertion upstream of blaOXA-23, which was associated with imipenem resistance (0.011). The blaOXA-24 gene was present in 55.2 % of the isolates, but showed no association with resistance to imipenem. The blaOXA-143 gene and the blaOXA-51 upstream insertion ISAba1 were common, but did not enhance imipenem resistance. The blaOXA-58, blaNDM and blaKPC genes were rare, which prevented us from analysing their relationship with resistance. After adjustment by logistic regression, blaOXA-23 was the only gene that was associated with resistance to imipenem (P=0.012). ISAba1 upstream of blaOXA-23 was analysed in another logistic regression model to assess collinearity with this gene. An association with resistance to imipenem was observed (P=0.044), but the model was less explanatory and significant (Table 1) .
Of the seven isolates that were susceptible to imipenem, two did not harbour any of the previously described resistance genes or insertions and three only had one gene or insertion. Interestingly, the other two isolates that were susceptible to imipenem had at least three resistance genes, including blaOXA-23. One also had the ISaba1 insertion upstream of blaOXA-23 (Table S2) .
MLST was performed in 35 of the 87 isolates, which were selected in proportion to the distribution of samples from the two hospitals. Thirteen STs were identified (Table 2) ; the most frequent was ST1 (n=9, 25.7 %), followed by ST162 (n=8, 22.8 %) and ST730 (n=6, 17.1 %). Four new STs -ST981, ST982, ST986 and ST988 -were identified and registered in PubMLST (https://pubmlst.org/abaumannii/, appendix A). Only one of the 35 isolates was sensitive to imipenem (ST162). The 13 STs belonged to 5 different CCs according to an analysis using eBURST (Fig. 1) ; 11 isolates (31.4 %) clustered in CC1 (ST1, ST986 and ST988), 10 (28.6 %) clustered in CC79 (ST79, ST169, ST175 and ST730) and 9 (25.7 %) clustered in CC162 (ST162 and ST982). One of the newly identified STs (ST981) was a singleton (Fig. 2) , although it was phylogenetically close to the CC15 isolates (n=3, 8.6 %).
Factors associated with mortality
Of the 87 patients infected with A. baumannii, 38 died in the hospital (43.7 %). There was no difference in mortality between sexes or between the two hospitals. Seven isolates that were sensitive to imipenem, meropenem and cefepime were from patients who survived the infection. There was no association between the examined A. baumannii genes and mortality rate. The following factors were found to be independently associated with mortality: age >60 years (P=0.029), nosocomial respiratory infection (P=0.008) and the need for norepinephrine infusion (P=0.014) ( Table S3 ).
The mortality rate among the 35 patients analysed by MLST was 42.8 %. Mortality was higher (83.3 %) among patients infected with ST730 than in those belonging to the other STs (P=0.023). On the other hand, mortality was lower in patients with isolates belonging to ST162 (12.5 %) as compared to all other STs (P=0.023). Multivariate analysis revealed an independent association between mortality and older age and ST730, while ST162 was associated with a higher probability of survival (Table 3) .
DISCUSSION
The study group presented pathologies and complications that are common in severely ill patients who require intensive care and are required to undergo to multiple invasive procedures. These patients are highly susceptible to nosocomial infections and associated morbidity and mortality. A. baumannii is one of the main micro-organisms responsible for such infections, especially VAP; its resistance to antimicrobial agents is of great concern and has been the focus of many investigations.
Among the clinical factors analysed in this study, three were associated with a worse prognosis: age >60 years old, use of norepinephrine and pneumonia. Advanced age is clearly a risk factor for unfavourable courses in patients with severe infection. The use of norepinephrine is an indicator of haemodynamic instability and infection severity. VAP was the most common nosocomial infection in this study and was an independent risk factor for mortality, consistent with previous reports [1] [2] [3] .
A large percentage of the A. baumannii isolates analysed in this study showed resistance to imipenem and other drugs, as well as sensitivity to polymyxin B, similar to trends reported in other regions of Brazil and other countries [8, 13, 15, 16, [26] [27] [28] . Among the genes that confer resistance to imipenem, blaOXA-23 is one of the most frequently described [14-16, 26, 29-32] ; the ISAba1 sequence upstream of this gene is known to increase its expression 
a, Clonal complex according to the eBURST classification.
b, ST981 was identified for the first time in this study and is close to CC15 but was classified as a singleton by eBURST. [12, 13, 23, 33] . Both were prevalent among the examined isolates and were associated with resistance to carbapenems.
Other genes associated with carbapenem resistance were detected in our samples, including blaOXA-24 and blaOXA-143, as well as the ISAba1 insertion upstream of blaOXA-51; however, these associations were not statistically significant. The lack of statistical association between these genes and resistance to carbapenems can be justified by the much higher blaOXA-23 gene prevalence and the fact that only seven isolates were sensitive to the antimicrobial. Furthermore, statistical association could have been revealed if our sample was larger.
The blaOXA-24 gene is prevalent in Jordan and Croatia, although it has rarely been isolated or even detected in Middle Eastern and European countries [26, 27, 30, 33, 34] . In Latin America, the blaOXA-72 variant of blaOXA-24 has been reported in Mexico and Ecuador [14, 28] . In Brazil, blaOXA-24 was not found in two studies comprising 110 and 155 samples from different regions [15, 16] , while blaOXA-72 was only rarely present in isolates in the Northeast, South and Southeast [35] [36] [37] . In contrast, blaOXA-24 was the second most frequently detected resistance gene (55.2 %) in our samples. The blaOXA-143 gene, which has variants that have been described in the United States, India and Honduras, has also been detected in southeastern and southern Brazil [35, [38] [39] [40] [41] [42] . This was in agreement with our findings in the Brazilian Central region, with 28.7 % of isolates harbouring this gene.
The blaOXA-58 gene has a low frequency in European and African countries, as well as in Brazil [15, 16, 26, 30, 32] . In addition, studies in Europe have shown that the frequency of this gene is declining, while the frequency of blaOXA-23 is increasing [26, 33, 34, 43, 44] . The blaOXA-58 gene was also uncommon in the present study.
It is interesting to note that even genes that are frequently associated with resistance are present in imipenem-susceptible isolates. Of the seven imipenem-sensitive isolates in our sample, two had none of the resistance genes that were tested, while three had only a single gene. Curiously, two imipenem-susceptible A. baumannii isolates had at least three genes conferring resistance to carbapenems, including blaOXA-23. Many molecular studies on A. baumannii focus solely on imipenem-resistant isolates [15, 19, 20, 26] . However, the presence of blaOXA-23 in isolates that are susceptible to carbapenems has been documented by Wallace et al [45] . Similarly, blaOXA-58-harbouring A. baumannii isolates with a large MIC range (1-16 µg ml À1 ) for imipenem and meropenem have been detected in China [46] . We did not perform other assays to explain these findings, but a heterogeneity in the resistance to carbapenems has been suggested as an underlying factor [47, 48] .
The frequency of the blaKPC and blaNDM genes -which belong to the Ambler A and B classes, respectively -was low, which is in agreement with results from other countries [14-16, 33, 49-51] . Phylogenetic classification by MLST revealed a predominance of ST1, ST162 and ST730. ST1, which belongs to CC1, is among the most common sequence types in South America and Brazil. Other STs that are prevalent on the continent, such as ST15 (CC15) and ST79 (CC79) [14, 16, 20] , were rarely detected in our study. On the other hand, we identified four new STs.
Most studies describing the STs of A. baumannii in a given region or hospital have focused on the genotype and phenotype of isolates. However, few have investigated the relationship between genotype and the clinical characteristics of or outcomes for patients. Some studies have suggested that ST10 (LAC-4) is associated with increased virulence in rats [52, 53] , whereas ST79 may be linked to lower mortality [54] . ST162 (CC162), the second most prevalent ST in our samples (22.8 %), was initially described in the Republic of Korea [55] and has been detected in Rio de Janeiro, Brazil [16] . In the present study, multivariate analysis showed that mortality was lower among patients harbouring ST162, independently of other variables. ST730, the third most frequent ST (17.1 %), was initially described in the South and Southeast regions of Brazil and, unlike ST162, was found to be independently associated with higher lethality in our study. Previous studies in Brazil reporting on ST730 did not mention any relationship with higher morbidity and mortality [19, 37] . Interestingly, ST730 belongs to CC79; the original member of this CC is ST79, which has been linked to lower mortality in Spain [54] .
One limitation of the present study is that only 35 isolates were used for MLST. Consequently, the results of the multivariate analysis should be interpreted with caution, since the small number of samples may have yielded spurious associations. However, the parameters of the logistic model were valid and indicated that clones ST162 and ST730 had lower and higher virulence, respectively, and therefore merit more detailed investigation.
Conclusion
Our study showed the high frequency of carbapenem-resistant A. baumannii isolates in two hospitals in a city in Central Brazil. blaOXA-23 (with its upstream insertion ISAba1) was the A. baumannii gene most frequently linked to carbapenem resistance. The blaOXA-24 gene, which is rarely found in Brazilian A. baumannii isolates, was present in 55 % of those examined in this study. Other less common carbapenem resistance genes (blaOXA-143 and blaOXA-58) were also detected. The genotype analysis identified CCs and STs that are common in Brazil and South America. The predominant CCs were CC1, CC79 and CC162. Some STs were described here for the first time. The factors associated with death were age >60 years, respiratory infection and receipt of infusions of norepinephrin. The STs ST730 and ST162 were independently associated with patient mortality and survival, respectively. These associations require confirmation by studies with a larger sample size; however, our findings suggest that genotype classification can serve as a prognostic tool for A. baumannii infection. 
